Bioblast Pharma

Hope should not be rare

Latest Developments Archive

Latest Developments Archive

  • May 25, 2016
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Reports First Quarter 2016 Financial Results

NEW HAVEN, Conn., May 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2016.

“During the first quarter, we announced positive final results of our HOPEMD open label Phase 2a study of trehalose 90mg/mL IV solution in patients with oculopharyngeal muscular dystrophy (OPMD),” said Colin Foster, Bioblast’s President and CEO.  “Trehalose 90mg/mL IV solution was observed to be safe and well tolerated, with no drug-related serious adverse events.  Additionally, improvements versus baseline were observed in multiple efficacy endpoints related to dysphagia and muscle strength and function.” 

“We ended the quarter with $21.6 million in cash and equivalents,” Mr. Foster, continued, “and are working on plans to reduce expenses going forward, such that we will be able to meet our operating objectives.” 

Continue reading

  • March 17, 2016
  • Bioblast Pharma
  • Latest developments

BioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering

NEW HAVEN, Conn., March 17, 2016 (GLOBE NEWSWIRE) — BioBlast Pharma Ltd. (Nasdaq:ORPN) (the “Company” or “ORPN”) announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the issuance of approximately 2.16 million ordinary shares at a purchase price per share of $3.10 in a registered direct offering and warrants to purchase up to approximately 1.08 million ordinary shares with an exercise price of $4.50 with gross proceeds of approximately $6.7 million.  The warrants are initially exercisable six months following issuance and have a term of five and one-half years following issuance.

Roth Capital Partners and Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agents for this transaction.

The closing of the sale of the securities is expected to take place on or about March 22, 2016, subject to satisfaction of customary closing conditions.

Continue reading

  • March 10, 2016
  • Bioblast Pharma
  • Latest developments

BioBlast Pharma to Present Corporate Overview at the 28th Annual ROTH Conference

NEW HAVEN, Conn., March 10, 2016 (GLOBE NEWSWIRE) — BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and CEO, will provide a corporate overview and business update at the 28th Annual ROTH Conference, taking place in Orange County, California, March 13-16, 2016.

Presentation Details:

Title:28th Annual ROTH ConferenceDate:Tuesday, March 15, 2016Time:8:00am Pacific TimeLocation:Ritz Carlton, Orange County, CaliforniaWebcast:http://wsw.com/webcast/roth30/orpn

Continue reading

Pages